Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Neal Shore, MD, Carolina Urologic Research Center

Interview

Darolutamide Plus ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

09/01/2022

Neal Shore, MD, shares insights about the recent FDA approval of darolutamide plus ADT and docetaxel for patients with metastatic hormone-sensitive prostate cancer and the data that led to this approval.

Neal Shore, MD, shares insights...

09/01/2022

Oncology

Videos

Enzalutamide Added to Testosterone Suppression Improves OS in Metastatic Hormone-Sensitive Prostate Cancer

07/21/2022

Ian Davis, MBBS, PhD, FRACP, FAChPM, discusses updated OS outcomes from the ENZAMET trial, exploring testosterone suppression plus either enzalutamide or a conventional non-steroidal anti-androgen in metastatic hormone-sensitive prostate...

Ian Davis, MBBS, PhD, FRACP,...

07/21/2022

Oncology

Videos

Dr Tward Discusses 2022 Anticipated Prostate Cancer Advancements Part 2

02/28/2022

In part two of this series, Dr Tward, MD, Huntsman Cancer Institute, discusses use of the Polaris test to prognosticate metastasis of men undergoing radiation therapy with prostate cancer, as well as ongoing efforts to further advance...

In part two of this series, Dr...

02/28/2022

Oncology

Jonathan Tward, MD, Huntsman Cancer Institute

Videos

Dr Jonathan Tward Discusses New and Upcoming Advancements for Prostate Cancer: Part 1

02/28/2022

In part one of this series, Dr Jonathan Tward, MD, Huntsman Cancer Institute, reviews ongoing efforts to further advance personalized treatment in the prostate cancer space.

In part one of this series, Dr...

02/28/2022

Oncology

Dr Chi, MD, Discusses Phase 3 MAGNITUDE, SPARTAN, and TITAN Study Results

02/17/2022

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Kim Chi, MD, Vancouver Prostate...

02/17/2022

Oncology

Videos

Dr Tagawa Discusses Study Results of Actinium J591 for mCRPC

06/22/2021

Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.

Scott Tagawa, MD, MS, FACP,...

06/22/2021

Oncology

Interview

Dr Schweizer Talks Concordance of DDR Mutations in Paired Primary, Metastatic Prostate Cancer Samples

06/15/2021

Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.

Michael Schweizer, MD, Seattle...

06/15/2021

Oncology

Videos

Dr Agarwal Discusses Final Analysis Results of the TITAN Study - Part 1

06/15/2021

In part one of this video series, Neeraj Agarwal, MD, discusses HRQoL and patient-reported outcomes at final analysis of the TITAN study being presented at the virtual 2021 ASCO Annual Meeting.

In part one of this video...

06/15/2021

Oncology

Videos

Dr Tagawa Talks Final Analysis Results of the TITAN Study

06/08/2021

Scott Tagawa, MD, MS, FACP, provides commentary on the results of TITAN, a phase III study of apalutamide in patients with mCSPC receiving androgen deprivation therapy.

Scott Tagawa, MD, MS, FACP,...

06/08/2021

Oncology

Interview

Dr Labanca Talks Use of Non-Canonical AR Signaling, Ketone Body Fuel in CRPC

05/03/2021

Estefania Labanca, PhD, discusses data on CRPC progression and the use of non-canonical AR signaling and ketone body fuel which were presented at the AACR Annual Meeting.

Estefania Labanca, PhD,...

05/03/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology